Loleta D. Harris - Concepedia

Author

Loleta D. Harris

The University of Texas MD Anderson Cancer Center

Also Known As

L. Harris, Loleta D. Harris, Loleta Harris

Publications

341

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center St. Jude Children's Research Hospital University of Tennessee Health Science Center

About

Loleta D. Harris is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell division, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	236
2	Cell Biology	3	3	190
3	Engineering	1	1	36
4	Molecular Biology	1	1	85
5	Pathology	1	1	36

Loleta D. Harris

Publications

322

Citations

H-Index

Page 1

	Year	Citations
Spindle checkpoint function requires Mad2-dependent Cdc20 binding to the Mad3 homology domain of BubR1 James H. Davenport, Loleta D. Harris, Rakesh Goorha Experimental Cell Research Signal TransductionCell DivisionMad2-dependent Cdc20 BindingMolecular BiologyMad3 Homology Domain	2006	85
The Mouse Mitotic Checkpoint Gene Bub1b, a Novel Bub1 Family Member, Is Expressed in a Cell Cycle-Dependent Manner J. W. Davenport, Elma R. Fernandes, Loleta D. Harris, Genomics ChromatinCell DivisionGeneticsCell CycleTumor Suppressor	1999	66
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells Edmund Chiong, I-Ling Lee, Ali Dadbin, Clinical Cancer Research	2011	66
The mitotic checkpoint gene BubR1 has two distinct functions in mitosis Loleta D. Harris, James H. Davenport, Geoffrey Neale, Experimental Cell Research Genome InstabilityCell RegulationCell DivisionMedicineGenetics	2005	39
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray Loleta D. Harris, Jorge de la Cerda, Tomasz Tuziak, Molecular Carcinogenesis EngineeringPathologyCancer BiologyTumor BiologyAberrant Localization Patterns	2008	36
The Use of Short Tandem Repeat Profiling to Characterize Human Bladder Cancer Cell Lines Edmund Chiong, Ali Dadbin, Loleta D. Harris, The Journal of Urology	2009	20
Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC) Stacey Moulder, Monica Mita, C. R. Bradley, Cancer Research Phase 1BMetastatic Breast CancerBreast OncologyChemoprevention StrategyMedicine	2010	10

Page 1